MedTrace Logo

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

NCT06303713 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-04-08

No results posted yet for this study

Summary

The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective in shrinking or preventing growth of prostate cancer.

The names of the study drugs used in this research study are:

* Carboplatin (A type of chemotherapy)
* 177Lu-PSMA-617 (A type of radioligand therapy)

Conditions

Interventions

DRUG

Carboplatin

Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.

DRUG

177Lu-PSMA-617

Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

Principal Investigators

  • Praful Ravi, MB BCHir, MRCP · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2026-10-19
Completion
2027-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06303713 on ClinicalTrials.gov